Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 306 participants.

Also called NCT04686643

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 306 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04686643
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04686643. Randomized; double masking; primary purpose treatment. Start 2021-02-01 (anticipated); primary completion 2022-02-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension
Condition
Hypertension
Intervention (Drug)
AGSAVI
Intervention (Drug)
AGLS
Lead sponsor
Ahn-Gook Pharmaceuticals Co.,Ltd (class: industry)

Record details

Record id
cardio:ct-nct04686643
Content hash
2afba1dca4ffdfad4a0daed57eab9297039ecafc1723561bd8c40235acb796d3